The Group is the world's first to create a "Engineering R&D + Inspection and Testing + Clinical Trials + Registration" one-stop service platform for the entire industry chain. Relying on Beijing Zhongguancun Shuimu Medical Technology Co., Ltd., Beijing Shuimu Jingchuang Pharmaceutical Technology Co., Ltd., Beijing Shuimu Jiheng Biotechnology Co., Ltd., and Chengdu Shuimu Medical Technology Co., Ltd. under the Group, it provides "end-to-end" integrated innovative services for different stages of the entire life cycle of medical device products.

Currently, the Group's business has covered the whole country, and its business development has entered the fast track. As of the end of 2021, the Group has served more than 200 clients, with projects focused on high-end medical devices and in vitro diagnostic products, including the world's smallest proton therapy device, the world's first split medical robot, the country's first heavy ion therapy project, new coronavirus test reagents, in vitro diagnostic reagent standards, and quality control products.

The Group ensures the product registration efficiency of medical device companies through scientific operation processes and strict quality control systems, minimizing review risks and accelerating the pace of product listing.

In September 2021, the State Administration for Market Regulation issued the "Guidance on Further Deepening Reform to Promote the Improvement and Strengthening of the Inspection and Testing Industry", proposing to deepen reform, promote the market-oriented development of inspection and testing institutions, encourage social capital to enter the inspection and testing industry, encourage private enterprises and other social capital to invest in inspection and testing services, support qualified enterprises to apply for relevant qualifications, and provide inspection and testing services to the society.

Under this historical opportunity, the Group will continue to pursue excellence, advocate quality, and have integrity. At the same time, it will take advantage of the momentum, aim at the international technological frontier, further strengthen the technical platform and inspection and testing technology standard system construction, expand capabilities, participate in the design and development of inspection and testing instruments and equipment, reagents and consumables, standard materials, provide "one-stop" services based on quality, achieve "integrated" development, help medical device companies improve R&D innovation and technology iteration efficiency, explore more efficient medical research and production transformation pathways, provide high-quality, efficient, and convenient comprehensive services to the society, and build a one-stop service platform for the industrialization of medical devices.